These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 33028591)
1. Preclinical Comparison of the Blood-brain barrier Permeability of Osimertinib with Other EGFR TKIs. Colclough N; Chen K; Johnström P; Strittmatter N; Yan Y; Wrigley GL; Schou M; Goodwin R; Varnäs K; Adua SJ; Zhao M; Nguyen DX; Maglennon G; Barton P; Atkinson J; Zhang L; Janefeldt A; Wilson J; Smith A; Takano A; Arakawa R; Kondrashov M; Malmquist J; Revunov E; Vazquez-Romero A; Moein MM; Windhorst AD; Karp NA; Finlay MRV; Ward RA; Yates JWT; Smith PD; Farde L; Cheng Z; Cross DAE Clin Cancer Res; 2021 Jan; 27(1):189-201. PubMed ID: 33028591 [TBL] [Abstract][Full Text] [Related]
2. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity. Ballard P; Yates JW; Yang Z; Kim DW; Yang JC; Cantarini M; Pickup K; Jordan A; Hickey M; Grist M; Box M; Johnström P; Varnäs K; Malmquist J; Thress KS; Jänne PA; Cross D Clin Cancer Res; 2016 Oct; 22(20):5130-5140. PubMed ID: 27435396 [TBL] [Abstract][Full Text] [Related]
3. YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer. Yun J; Hong MH; Kim SY; Park CW; Kim S; Yun MR; Kang HN; Pyo KH; Lee SS; Koh JS; Song HJ; Kim DK; Lee YS; Oh SW; Choi S; Kim HR; Cho BC Clin Cancer Res; 2019 Apr; 25(8):2575-2587. PubMed ID: 30670498 [TBL] [Abstract][Full Text] [Related]
4. Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC). Martinez-Marti A; Felip E; Matito J; Mereu E; Navarro A; Cedrés S; Pardo N; Martinez de Castro A; Remon J; Miquel JM; Guillaumet-Adkins A; Nadal E; Rodriguez-Esteban G; Arqués O; Fasani R; Nuciforo P; Heyn H; Villanueva A; Palmer HG; Vivancos A Ann Oncol; 2017 Oct; 28(10):2451-2457. PubMed ID: 28961841 [TBL] [Abstract][Full Text] [Related]
5. Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer. Fukuda K; Otani S; Takeuchi S; Arai S; Nanjo S; Tanimoto A; Nishiyama A; Naoki K; Yano S Cancer Sci; 2021 Sep; 112(9):3784-3795. PubMed ID: 34145930 [TBL] [Abstract][Full Text] [Related]
6. Comparison of the Efficacy of EGFR Tyrosine Kinase Inhibitors Erlotinib and Low-dose Osimertinib on a PC-9-GFP Katsuya Y; Miyake K; Higuchi T; Oshiro H; Sugisawa N; Singh SR; Goto Y; Zhao M; Hoffman RM In Vivo; 2020; 34(3):1027-1030. PubMed ID: 32354888 [TBL] [Abstract][Full Text] [Related]
7. The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M. Huang YH; Tseng JS; Hsu KH; Chen KC; Su KY; Yu SL; Chen JJW; Yang TY; Chang GC Sci Rep; 2021 Jun; 11(1):12084. PubMed ID: 34103652 [TBL] [Abstract][Full Text] [Related]
8. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib. Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539 [TBL] [Abstract][Full Text] [Related]
9. A PET study in healthy subjects of brain exposure of Varrone A; Varnäs K; Jucaite A; Cselényi Z; Johnström P; Schou M; Vazquez-Romero A; Moein MM; Halldin C; Brown AP; Vishwanathan K; Farde L J Cereb Blood Flow Metab; 2020 Apr; 40(4):799-807. PubMed ID: 31006308 [TBL] [Abstract][Full Text] [Related]
10. Osimertinib: A third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation. Bollinger MK; Agnew AS; Mascara GP J Oncol Pharm Pract; 2018 Jul; 24(5):379-388. PubMed ID: 28565936 [TBL] [Abstract][Full Text] [Related]
11. Rapid intracranial response to osimertinib, without radiotherapy, in nonsmall cell lung cancer patients harboring the EGFR T790M mutation: Two Case Reports. Koba T; Kijima T; Takimoto T; Hirata H; Naito Y; Hamaguchi M; Otsuka T; Kuroyama M; Nagatomo I; Takeda Y; Kida H; Kumanogoh A Medicine (Baltimore); 2017 Feb; 96(6):e6087. PubMed ID: 28178168 [TBL] [Abstract][Full Text] [Related]
12. Insight into the Therapeutic Selectivity of the Irreversible EGFR Tyrosine Kinase Inhibitor Osimertinib through Enzyme Kinetic Studies. Zhai X; Ward RA; Doig P; Argyrou A Biochemistry; 2020 Apr; 59(14):1428-1441. PubMed ID: 32207968 [TBL] [Abstract][Full Text] [Related]
13. Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation. Miyashita Y; Ko R; Shimada N; Mitsuishi Y; Miura K; Matsumoto N; Asao T; Shukuya T; Shibayama R; Koyama R; Takahashi K Thorac Cancer; 2021 Feb; 12(3):329-338. PubMed ID: 33219754 [TBL] [Abstract][Full Text] [Related]
14. MET amplification results in heterogeneous responses to osimertinib in EGFR-mutant lung cancer treated with erlotinib. Nishiyama A; Takeuchi S; Adachi Y; Otani S; Tanimoto A; Sasaki M; Matsumoto S; Goto K; Yano S Cancer Sci; 2020 Oct; 111(10):3813-3823. PubMed ID: 32735723 [TBL] [Abstract][Full Text] [Related]
15. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy. Park S; Lee MH; Seong M; Kim ST; Kang JH; Cho BC; Lee KH; Cho EK; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ Ann Oncol; 2020 Oct; 31(10):1397-1404. PubMed ID: 32634610 [TBL] [Abstract][Full Text] [Related]
16. Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein). van Hoppe S; Jamalpoor A; Rood JJM; Wagenaar E; Sparidans RW; Beijnen JH; Schinkel AH Pharmacol Res; 2019 Aug; 146():104297. PubMed ID: 31175939 [TBL] [Abstract][Full Text] [Related]
17. Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis. Hirashima T; Satouchi M; Hida T; Nishio M; Kato T; Sakai H; Imamura F; Kiura K; Okamoto I; Kasahara K; Uchida H; Vowler SL; Mitsudomi T Cancer Sci; 2019 Sep; 110(9):2884-2893. PubMed ID: 31265163 [TBL] [Abstract][Full Text] [Related]
18. Prospective Observational Study of Treatment Resistance-related Gene Screening Using Plasma Circulating Tumor DNA in Third-generation EGFR-TKI Osimertinib Therapy (Elucidator). Tamiya A; Isa SI; Taniguchi Y; Nakagawa H; Atagi S; Ando M; Koh Y Clin Lung Cancer; 2021 May; 22(3):e336-e341. PubMed ID: 32641247 [TBL] [Abstract][Full Text] [Related]
19. Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib/Erlotinib? Tamiya M; Tamiya A; Suzuki H; Moriizumi K; Nakahama K; Taniguchi Y; Kunimasa K; Kimura M; Inoue T; Kuhara H; Nishino K; Hirashima T; Atagi S; Imamura F; Kumagai T Anticancer Res; 2019 Jul; 39(7):3923-3929. PubMed ID: 31262922 [TBL] [Abstract][Full Text] [Related]
20. Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer. Cai X; Miao J; Sun R; Wang S; Molina-Vila MA; Chaib I; Rosell R; Cao P Pharmacol Res; 2021 Aug; 170():105701. PubMed ID: 34087353 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]